AMA Report Urges Boost In Research

CHICAGO—A five-year study by the American Medical Association and 171 other public and private organizations to influence the future of health care policy in the United States has recommended a 10 percent annual increase in NIH funding, tax breaks for pharmaceutical and other companies that conduct biomedical research and increased cooperative ventures between universities and private industry. The report's findings were summarized here February 16 at the annual meeting of the American Ass

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The report's findings were summarized here February 16 at the annual meeting of the American Association for the Advancement of Science; the complete report, titled "A Health Planning Agenda for the American People," was unveiled one week later at a press conference in Washington, D.C.

The report covers six major areas of health care policy, including medical science, and contains proposals based on 159 principles of health care. The AMA has spent $7 million on the project since it was begun in 1982, and has collected an additional $5 million from other professional societies, drug and insurance companies, foundations and nonprofit organizations involved in the study. A total of 435 people participated in the exercise.

The report's basic prescription for medical science is more money—from the federal government, which the report said has "the primary responsibility for assuming the viability of the nation's biomedical research enterprise," as well as from ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies